Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.

about

Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.Monoclonal antibodies against cutaneous T-cell lymphomas.

P2860

Q48265648-8B131B4F-DE70-4973-B81E-3B455886196B Q51803389-6AFA9943-C459-4C96-B537-960DA8E1A811

P2860

Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.

Item

http://www.wikidata.org/entity/Q38812806

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Brentuximab vedotin in pretrea ...... atic review and meta-analysis.

@en

type

Item

label

Brentuximab vedotin in pretrea ...... atic review and meta-analysis.

@en

prefLabel

Brentuximab vedotin in pretrea ...... atic review and meta-analysis.

@en

P1476

Brentuximab vedotin in pretrea ...... atic review and meta-analysis.

@en

P2093

Jamal Zekri

http://www.w3.org/2001/XMLSchema#string

Rawan Al Saadi

http://www.w3.org/2001/XMLSchema#string

Reyad Dada

http://www.w3.org/2001/XMLSchema#string

P2860

Rehabilitation following carpal tunnel release

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.

Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia.

Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.

P304

739-745

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1080/14712598.2016.1180362

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27096887

http://www.w3.org/2001/XMLSchema#string

Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.

about

P2860

P2860

Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698